Beacon Equity Research announces the release of Trade Alerts covering market movers: Geron Corp. (Nasdaq: GERN), Rohm & Haas Co. (NYSE: ROH), StemCells Inc. (Nasdaq: STEM), Sprint Nextel Corp. (NYSE: S), Schering-Plough Corp. (NYSE: SGP) and Dell Inc. (Nasdaq: DELL).
In the Trade Alert, the author highlights Geron’s announcement it received approval from the FDA to initiate the first-ever study of a treatment based on human embryonic stem cells:
“Geron Corp. (GERN) shares fell 7.54% to hit $4.17 this morning after yesterday’s impressive gain. Geron, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. … Geron was a huge winner among biotech stocks yesterday after President Obama signed an executive order that removes restrictions on government funding for embryonic stem cell research set by former President George W. Bush in 2001. The news has been widely anticipated since the election, as President Obama had pledged on the campaign trail to overturn the ban. … In late January, Geron announced it received approval from the FDA to initiate the first-ever study of a treatment based on human embryonic stem cells. FDA has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. Geron president and CEO Thomas B. Okarma, Ph.D., M.D., has said that the FDA’s clearance of its GRNOPC1 IND is one of Geron’s most significant accomplishments to date.”
The Trade Alert author also featured Dow Chemicals’ agreement to buy Rohm & Haas under terms agreed upon in July:
“Rohm & Haas Co. (ROH) shares increased 4.91% to $77.63 in today’s early trading. Rohm & Haas provides various specialty materials primarily for use in the building and construction, electronics, packaging and paper, industrial, transportation, household, personal care, water and food markets. … Moving forward on its disputed $15 billion buyout of Rohm & Haas, Dow Chemicals agreed to buy the company under terms similar to the $78 a share agreed upon in July, the companies announced in a joint statement. … It was reported that Dow Chemical, the largest U.S. chemical maker, had put the deal on hold in January following the financial crisis and the economic downturn, saying now wasn't the time to swallow such a large acquisition. Consequently, Rohm & Haas filed suit against Dow after the chemical giant said it was unable to proceed with the acquisition.”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
BeaconEquity.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
